Akorn Inc. has voluntarily recalled 5,380 cartons of Fentanyl Citrate Injection, USP, 100 mcg/2 mL (50 mcg/mL) because stability testing at the 12-month mark revealed impurity levels of 4.0%, which exceeds the safety limit of 3.0%. Each recalled carton contains 25 glass ampules of the medication. Consumers and healthcare providers should check their inventory for the specific lot number and expiration date affected by this quality failure.
The presence of impurities above the approved threshold can alter the drug's effectiveness or safety profile. While the risk level is currently considered low, out-of-specification degradation products can potentially cause adverse reactions or lead to insufficient pain management.
AI-Enhanced Content: The summary, action steps, and risk assessment on this page were generated by AI from official government recall data to improve readability. This is not legal or medical advice. Always refer to the official agency sources below for authoritative information.
Sources: FDA iRES ยท Raw API Response
openFDA Disclaimer: This recall information is sourced from the openFDA API. Do not rely on openFDA to make decisions regarding medical care. While we make every effort to ensure that data is accurate, you should assume all results are unvalidated. Refer to the openFDA terms of service for more information.